Table 2.

Frequency, and intensity of adverse effects observed on 753 patients treated with MDT

Signs and Symptoms		Absent		Mild		Moderate		Severe		Total
		N	%	N	%	N	%	N	%	N	%
Skin pigmentation		8298	78.3%	1715	16.2%	572	5.4%	14	0.1%	10599	100%
Xerosis		8813	83.1%	1444	13.6%	297	2.8%	46	0.4%	10600	100%
Itch		10252	96.7%	280	2.6%	56	0.5%	10	0.1%	10598	100%
Headache		10278	97.0%	287	2.7%	34	0.3%	1	0.0%	10600	100%
Paleness		10286	97.0%	284	2.7%	27	0.3%	3	0.0%	10600	100%
Fatigue		10363	97.8%	214	2.0%	20	0.2%	2	0.0%	10599	100%
Myalgia		10389	98.0%	184	1.7%	24	0.2%	3	0.0%	10600	100%
Anorexia		10458	98.7%	118	1.1%	24	0.2%	0	0.0%	10600	100%
Dyspnea		10475	98.8%	109	1.0%	16	0.2%	0	0.0%	10600	100%
Nausea		10484	98.9%	97	0.9%	17	0.2%	2	0.0%	10600	100%
Abdominal pain		10485	98.9%	97	0.9%	13	0.1%	5	0.0%	10600	100%
Weight loss		10496	99.0%	92	0.9%	12	0.1%	0	0.0%	10600	100%
Fever		10499	99.1%	80	0.8%	20	0.2%	0	0.0%	10599	100%
Diarrhea		10524	99.3%	61	0.6%	15	0.1%	0	0.0%	10600	100%
Skin rash		10538	99.4%	41	0.4%	18	0.2%	1	0.0%	10598	100%
Constipation		10545	99.5%	47	0.4%	8	0.1%	0	0.0%	10600	100%
Erythroderma		10548	99.5%	26	0.2%	21	0.2%	5	0.0%	10600	100%
Photodermatosis		10552	99.5%	23	0.2%	24	0.2%	1	0.0%	10600	100%
Depression		10553	99.6%	37	0.3%	8	0.1%	0	0.0%	10598	100%
Bleeding		10562	99.6%	27	0.3%	11	0.1%	0	0.0%	10600	100%
Vomiting		10563	99.7%	26	0.2%	10	0.1%	1	0.0%	10600	100%
Cyanosis		10575	99.8%	17	0.2%	7	0.1%	1	0.0%	10600	100%
Jaundice		10579	99.8%	14	0.1%	7	0.1%	0	0.0%	10600	100%